CS-1008 + irinotecan
Phase 2Terminated 0 views this week 0 watching💤 Quiet
Interest: 27/100
27
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Metastatic Colorectal Cancer
Conditions
Metastatic Colorectal Cancer
Trial Timeline
Jul 1, 2009 → Dec 1, 2011
NCT ID
NCT00969033About CS-1008 + irinotecan
CS-1008 + irinotecan is a phase 2 stage product being developed by Daiichi Sankyo for Metastatic Colorectal Cancer. The current trial status is terminated. This product is registered under clinical trial identifier NCT00969033. Target conditions include Metastatic Colorectal Cancer.
What happened to similar drugs?
20 of 20 similar drugs in Metastatic Colorectal Cancer were approved
Approved (20) Terminated (8) Active (0)
Hype Score Breakdown
Clinical
12
Activity
0
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00969033 | Phase 2 | Terminated |
Competing Products
20 competing products in Metastatic Colorectal Cancer